多发性骨髓瘤:2022年诊断、风险分层与管理更新
多发性骨髓瘤约占血液系统恶性肿瘤的10%。诊断需克隆性骨髓浆细胞≥10%或活检证实的浆细胞瘤,并伴一项骨髓瘤定义事件。风险分层将del(17p)、t(4;14)、t(14;16)、t(14;20)、gain 1q或p53突变列为高危因素,含两项为双打击、三项及以上为三打击骨髓瘤。适合移植者诱导用VRd约3-4周期后行ASCT,高危者可用Dara-VRd替代VRd;不适合移植者用VRd约8-12周期后维持或DRd至进展。
要点
- 诊断需克隆性骨髓浆细胞≥10%或活检证实的浆细胞瘤,加一项骨髓瘤定义事件。
- 高危因素包括del(17p)、t(4;14)、t(14;16)、t(14;20)、gain 1q或p53突变。
- 适合移植者VRd诱导约3-4周期后ASCT,高危者可用Dara-VRd替代VRd。
核心结论
- 多发性骨髓瘤的诊断需克隆性骨髓浆细胞≥10%或活检证实的浆细胞瘤,并伴一项骨髓瘤定义事件;治疗按风险分层选择。
研究设计与样本
- 本文为多发性骨髓瘤2022年诊断、风险分层与管理更新的综述。
主要发现
- 多发性骨髓瘤约占血液系统恶性肿瘤的10%。
- 骨髓瘤定义事件包括归因于浆细胞病的CRAB(高钙血症、肾功能衰竭、贫血或溶骨性骨病变)、骨髓克隆性浆细胞≥60%、血清受累/未受累游离轻链(FLC)比值≥100(且受累FLC≥100 mg/L),或磁共振成像上>1个局灶性病变。
- del(17p)、t(4;14)、t(14;16)、t(14;20)、gain 1q或p53突变视为高危多发性骨髓瘤;含任意两项高危因素为双打击骨髓瘤,三项及以上为三打击骨髓瘤。
关键数值与推荐
- 适合自体干细胞移植者:硼替佐米、来那度胺、地塞米松(VRd)约3-4周期后行自体干细胞移植(ASCT);高危患者可用达雷妥尤单抗、硼替佐米、来那度胺、地塞米松(Dara-VRd)替代VRd。
- 部分选定的标危患者可采集干细胞、接受额外诱导周期并延迟移植至首次复发。
- 不适合移植者:VRd约8-12周期后维持,或达雷妥尤单抗、来那度胺、地塞米松(DRd)直至进展。
- 维持治疗:标危患者需要来那度胺维持,高危骨髓瘤需要硼替佐米联合来那度胺维持。
- 复发治疗通常需要三药方案,方案选择随每次连续复发而变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. DIAGNOSIS: The diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) attributable to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥ 100 (provided involved FLC is ≥100 mg/L), or >1 focal lesion on magnetic resonance imaging. RISK STRATIFICATION: The presence of del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation is considered high-risk multiple myeloma. The presence of any two high risk factors is considered double-hit myeloma, and three or more high risk factors is triple-hit myeloma. RISK-ADAPTED INITIAL THERAPY: In patients who are candidates for autologous stem cell transplantation, induction therapy consists of bortezomib, lenalidomide, dexamethasone (VRd) given for approximately 3-4 cycles followed by autologous stem cell transplantation (ASCT). In high-risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) is an alternative to VRd. Selected standard-risk patients can collect stem cells, get additional cycles of induction therapy, and delay transplant until first relapse. Patients who are not candidates for transplant are treated with VRd for approximately 8-12 cycles followed by maintenance or alternatively with daratumumab, lenalidomide, dexamethasone (DRd) until progression. MAINTENANCE THERAPY: Standard-risk patients need lenalidomide maintenance, while bortezomib plus lenalidomide maintenance is needed for high-risk myeloma. MANAGEMENT OF RELAPSED DISEASE: A triplet regimen is usually needed at relapse, with the choice of regimen varying with each successive relapse.
引用
- Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022. PMID: 35560063. doi:10.1002/ajh.26590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。